drugset
Drugs / Tranexamic Acid
last change 10 days ago re-read 9 days ago

Tranexamic Acid

also known as TXA · Cyklokapron · Kapron · Exacyl · Capron · LB1148 · Transamin · TNA · +24 more

Small molecule

Developed for
hemorrhagic disease · osteoarthritis, knee · hyperpigmentation of the skin · anemia · menstrual disorder · rotator cuff syndrome · arthropathy · bone disorder
+120 more · osteoarthritis · osteoarthritis, hip · bleeding disorder, vascular-type · coronary artery disorder · leiomyoma · traumatic brain injury · uterine disorder · benign prostatic hyperplasia · chronic rhinosinusitis · COVID-19 · craniosynostosis · hematopoietic and lymphoid cell neoplasm · ileus · placenta praevia · venous thromboembolism · blood coagulation disease · intracerebral hemorrhage · nephrolithiasis · pregnancy disorder · prostate cancer · scoliosis · acquired coagulation factor deficiency · active peptic ulcer disease · cardiac valvular defect · cirrhosis of liver · eyelid disorder · fibrinolytic defect · head and neck neoplasm · hemophilia · hereditary hemorrhagic telangiectasia · infectious disease with sepsis · lower respiratory tract disorder · lumbar spinal stenosis · meningioma · ovarian cancer · pelvic organ prolapse · shoulder impingement syndrome · tonsillitis · urinary bladder cancer · uterine corpus leiomyoma · vascular hemostatic disease · von Willebrand disease (hereditary or acquired) · abdominal aortic aneurysm · abdominal wall malformation · acute myeloid leukemia · adolescent idiopathic scoliosis · aortic disorder · arteriovenous hemangioma/malformation · chronic liver failure · chronic pain syndrome · colon carcinoma · conjunctival disorder · developmental dysplasia of the hip · disease of orbital part of eye adnexa · endometrial disorder · Ewing sarcoma of bone · female breast carcinoma · female reproductive system neoplasm · gastric cancer · gastric neoplasm · hemarthrosis · hemophilia A · hepatocellular carcinoma · hyperpigmentation of eyelid · hypotensive disorder · lichen planus pigmentosus · lung disorder · lymphedema · lymphocele · malignant pancreatic neoplasm · melanoma · metastatic malignant neoplasm in the spinal cord · myelodysplastic syndrome · myelodysplastic/myeloproliferative neoplasm · neoplasm of esophagus · obstetric disorder · osteogenesis imperfecta · osteoporosis · osteosarcoma · palmar fibromatosis · perianal hematoma · phlebectasia of lips · placenta accreta · placental abruption · platelet disorder, undefined · pneumonia · polyp of large intestine · skin disorder · skin squamous cell carcinoma · spinal stenosis · stomach polyp · thrombocytopenia · tumor of duodenum · upper digestive tract disorder · urethral stricture · urinary tract obstruction · varicose disease · vertebral column disorder · adenoid hypertrophy · alveolar periostitis · angiodysplasia of intestine · bronchial disorder · chronic urticaria · colorectal cancer · congenital heart disease · epilepsy · esophageal varices with bleeding · hereditary angioedema · intervertebral disk degenerative disorder · musculoskeletal system cancer · nosocomial infection · obesity disorder · skin infection · skin pigmentation disorder · soft tissue sarcoma · spinal cord disorder · spinal cord injury · subarachnoid hemorrhage · toe, misshapen · uterine anomalies
Investigated by
Cairo University · Assiut University · London School of Hygiene and Tropical Medicine · Aswan University Hospital · Chinese Academy of Medical Sciences, Fuwai Hospital · NYU Langone Health
+516 more · National Cheng-Kung University Hospital · Northwestern University · University Health Network, Toronto · Ferring Pharmaceuticals · St. Olavs Hospital · University of Alabama at Birmingham · Indonesia University · Konkuk University Medical Center · Ottawa Hospital Research Institute · Sant Pau Research Institute · Sunnybrook Health Sciences Centre · Al-Azhar University · Assaf-Harofeh Medical Center · Campbell Clinic · Canadian Institutes of Health Research (CIHR) · Clinical Hospital Centre Zagreb · Corewell Health West · George Washington University · Hamilton Health Sciences Corporation · Henry Ford Health System · Hospital for Special Surgery, New York · McMaster University · Ministry of Health, France · Montefiore Medical Center · National Heart, Lung, and Blood Institute (NHLBI) · Pfizer · RenJi Hospital · Rush University Medical Center · Tanta University · Thammasat University · University of California, San Francisco · University of Wisconsin, Madison · Washington University School of Medicine · Yonsei University · Albany Medical College · Asan Medical Center · Azienda U.S.L. 1 di Massa e Carrara · Bayer · Benha University · Boston Children's Hospital · Dalhousie University · Daniel Nishijima, MD, MAS · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · First Affiliated Hospital, Sun Yat-Sen University · HaEmek Medical Center, Israel · Haseki Training and Research Hospital · Hebei Medical University Third Hospital · Hua Luo · King Edward Medical University · Korea Health Industry Development Institute · M.D. Anderson Cancer Center · Massachusetts General Hospital · Meir Medical Center · Monash University · Mount Sinai Hospital, Canada · Nanfang Hospital, Southern Medical University · National Health and Medical Research Council, Australia · Oregon Health and Science University · Palisade Bio · Pediatric Emergency Care Applied Research Network · Population Health Research Institute · Rabin Medical Center · Rawalpindi Medical College · Second Affiliated Hospital of Guangzhou Medical University · Second Affiliated Hospital, School of Medicine, Zhejiang University · Seoul National University Hospital · Shanghai Jiao Tong University School of Medicine · Stanford University · Taipei Veterans General Hospital, Taiwan · The First Affiliated Hospital of Zhengzhou University · The Hospital for Sick Children · The Physicians' Services Incorporated Foundation · The University of Texas Health Science Center at San Antonio · The University of Texas Health Science Center, Houston · all 522 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Approved US (FDA) CYKLOKAPRON — 1986-12-30 fda.gov ↗
Filed US (FDA) — — —

“the U.S. FDA requested additional information about the Tranexamic Acid RTU filing.” hyloris.com ↗

Trials 449 · started per year

today
US approved 1986
1
1
1
5
7
2
9
9
10
7
13
17
21
22
26
17
35
26
30
44
29
31
31
21
33
1
19861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 018 trials · 1 met primary
Phase 0 NCT07565753 Jul 2026 → Sep 2027 expected bleeding disorder, vascular-type, tonsillitis The University of Texas Health Science Center at San Antonio Recruiting No outcome recorded
Phase 0 NCT07362992 Jul 2026 → Dec 2028 expected — Wolfson Medical Center Recruiting No outcome recorded
Phase 0 NCT06580509 Feb 2026 → Sep 2027 expected bleeding disorder, vascular-type, tonsillitis The University of Texas Health Science Center at San Antonio Recruiting No outcome recorded
Phase 0 NCT06725732 Jan → Dec 2025 overdue — Assiut University Recruiting No outcome recorded
Phase 0 NCT06345833 Jul 2024 → Jul 2026 overdue hemophilia, hemorrhagic disease University of Minnesota Recruiting No outcome recorded
Phase 0 NCT06097611 Nov 2023 → Nov 2024 — Assiut University Unknown No outcome recorded
Phase 0 NCT04630886 Jun 2021 → Jan 2024 skin neoplasm Riley McLean Terminated No outcome recorded
Phase 0 NCT04797156 Mar 2021 → Aug 2024 — Icahn School of Medicine at Mount Sinai Completed No outcome recorded
Phase 0 NCT04541303 Oct 2020 → Dec 2021 — University of Missouri-Columbia Completed Met primary
Phase 0 NCT04488367 Jul 2020 → Jul 2023 bone disorder Community Memorial Health System Unknown No outcome recorded
Phase 16 trials
Phase 1 NCT05774717 Apr 2023 → Apr 2029 expected — Vanderbilt University Medical Center Recruiting No outcome recorded
Phase 1 NCT03777488 Oct 2019 → Oct 2020 — London School of Hygiene and Tropical Medicine Completed No outcome recorded
Phase 1 NCT04100447 Nov 2018 → Mar 2020 ileus Ronald Hurst, MD, FACS Completed No outcome recorded
Phase 1 NCT02561923 Aug 2015 → Jun 2016 — Janssen Scientific Affairs, LLC Completed No outcome recorded
Phase 1 NCT02620748 Mar 2015 → Feb 2018 leiomyoma George Washington University Completed No outcome recorded
Phase 1 NCT01683955 Jan → Nov 2013 anemia, osteoarthritis, hip Henry Ford Health System Completed No outcome recorded
Phase 1/210 trials
Phase 1/2 NCT06983886 May 2025 → Jun 2026 overdue — Ramathibodi Hospital Not yet recruiting No outcome recorded
Phase 1/2 NCT06997796 May → Dec 2025 overdue — Dr. Anne Conlin Recruiting No outcome recorded
Phase 1/2 NCT06023212 Dec 2023 → Jan 2026 overdue metastatic malignant neoplasm in the spinal cord Second Affiliated Hospital, School of Medicine, Zhejiang University Recruiting No outcome recorded
Phase 1/2 NCT04555343 Mar → Sep 2021 prostate cancer, urinary bladder cancer, urinary tract obstruction Fraser Health Completed No outcome recorded
Phase 1/2 NCT03875937 Sep 2019 → Feb 2020 — London School of Hygiene and Tropical Medicine Completed No outcome recorded
Phase 1/2 NCT03806556 Apr 2019 → Aug 2020 acquired coagulation factor deficiency, childhood malignant neoplasm, hemorrhagic disease, thrombocytopenia Meghan McCormick Terminated No outcome recorded Stop: Enrollment
Phase 1/2 NCT02604719 Nov 2015 → May 2016 — Ahmed Alanwar Unknown No outcome recorded
Phase 1/2 NCT02688127 Aug 2015 → Feb 2016 pregnancy disorder Medical Research Council Completed No outcome recorded
Phase 1/2 NCT02350179 Jun 2014 → Apr 2015 perianal hematoma Ain Shams University Unknown No outcome recorded
Phase 1/2 NCT01085006 Sep 2009 → Aug 2010 hemorrhagic disease Tehran University of Medical Sciences Completed No outcome recorded
Phase 246 trials · 2 met primary · 2 missed
Phase 2 NCT07828262 Dec 2026 → Dec 2027 expected arthropathy Ottawa Hospital Research Institute Not yet recruiting No outcome recorded
Phase 2 NCT06665594 Dec 2025 → Nov 2026 expected — University of Wisconsin, Madison Recruiting No outcome recorded
Phase 2 NCT06718751 Oct 2025 → Oct 2029 expected — Baylor College of Medicine Not yet recruiting No outcome recorded
Phase 2 NCT06599762 Sep 2025 → Apr 2027 expected acute myeloid leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm University of Manitoba Recruiting No outcome recorded
Phase 2 NCT07263841 Jun → Dec 2025 overdue hyperpigmentation of the skin King Edward Medical University Active not recruiting No outcome recorded
Phase 2 NCT06644079 May 2025 → Apr 2026 skin squamous cell carcinoma University of Florida Withdrawn No outcome recorded
Phase 2 NCT06657924 Feb 2025 → Sep 2027 expected hemorrhagic disease, intestinal disorder, thrombotic disease Kristen Ban Recruiting No outcome recorded
Phase 2 NCT06057675 Mar 2024 → Aug 2027 expected skin cancer Vanderbilt University Medical Center Recruiting No outcome recorded
Phase 2 NCT03822793 Dec 2023 → Apr 2025 arthropathy University Hospital of Saint-Etienne Completed No outcome recorded
Phase 2 NCT05794321 Sep 2023 → May 2032 expected — University of California, San Francisco Recruiting No outcome recorded
Phase 2/314 trials · 2 met primary · 2 missed
Phase 2/3 NCT07212452 Aug → Oct 2025 — University of Health Sciences Lahore Completed Met primary
Phase 2/3 NCT06707051 Jan 2022 → Dec 2023 agranulocytosis, digestive system disorder, endometrial disorder, hemorrhagic disease +1 District Headquarters Teaching Hospital Sahiwal Completed No outcome recorded
Phase 2/3 NCT05047133 Sep 2021 → Jul 2022 overdue — Ascension Health Recruiting No outcome recorded
Phase 2/3 NCT04599205 Dec 2020 → Dec 2021 hyperpigmentation of the skin Assiut University Unknown No outcome recorded
Phase 2/3 NCT04430777 Jan 2019 → Feb 2020 — Total Definer Research Group Completed No outcome recorded
Phase 2/3 NCT03361345 Nov 2018 → Jan 2022 hyperpigmentation of the skin Wayne State University Withdrawn No outcome recorded Stop: Enrollment
Phase 2/3 NCT04170088 Sep 2018 → May 2019 drug allergy Jinnah Postgraduate Medical Centre Completed No outcome recorded
Phase 2/3 NCT03353259 Nov 2017 → Feb 2021 — Oslo University Hospital Terminated Met primary
Phase 2/3 NCT02866838 Dec 2016 → Sep 2021 intracerebral hemorrhage University Hospital, Basel, Switzerland Completed Missed primary
Phase 2/3 NCT03351686 Aug 2016 → Apr 2017 — Mansoura University Completed No outcome recorded
Phase 3102 trials · 8 met primary · 12 missed
Phase 3 NCT07825350 Jan 2027 → Jan 2030 expected osteoarthritis, knee Western University, Canada Not yet recruiting No outcome recorded
Phase 3 NCT04387305 Oct 2026 → Mar 2031 expected hemorrhagic disease, traumatic brain injury Daniel Nishijima, MD, MAS Not yet recruiting No outcome recorded
Phase 3 NCT07641946 Jul 2026 → Jul 2027 expected — Assiut University Not yet recruiting No outcome recorded
Phase 3 NCT07672158 Jul 2026 → Aug 2028 expected cerebral palsy Murdoch Childrens Research Institute Not yet recruiting No outcome recorded
Phase 3 NCT07474077 May 2026 → Dec 2027 expected — Sultan Qaboos University Not yet recruiting No outcome recorded
Phase 3 NCT06902714 Apr 2026 → Jul 2028 expected — University of Alabama at Birmingham Recruiting No outcome recorded
Phase 3 NCT07423156 Mar → Aug 2026 overdue placenta praevia Allama Iqbal Medical College Not yet recruiting No outcome recorded
Phase 3 NCT06519422 Sep 2025 → Aug 2028 expected anemia London School of Hygiene and Tropical Medicine Not yet recruiting No outcome recorded
Phase 3 NCT06337838 Jun 2025 → Feb 2027 expected acute kidney injury, chronic kidney disease, hemorrhagic disease Hamilton Health Sciences Corporation Recruiting No outcome recorded
Phase 3 NCT06070350 Nov 2024 → Jun 2028 expected — Philip Spinella Recruiting No outcome recorded
Phase 4139 trials · 9 met primary · 12 missed
Phase 4 NCT07869537 Oct 2026 → Mar 2027 expected hemorrhagic disease Second Affiliated Hospital, Zhejiang University, School of Medicine Recruiting No outcome recorded
Phase 4 NCT07853885 Oct 2026 → Apr 2027 expected osteoarthritis, knee The Second Affiliated Hospital of Kunming Medical University Not yet recruiting No outcome recorded
Phase 4 NCT07845747 Sep 2026 → Feb 2027 expected — Dow University of Health Sciences Enrolling by invitation No outcome recorded
Phase 4 NCT07685743 Sep 2026 → Mar 2028 expected osteoarthritis, hip, osteoarthritis, knee Oregon Health and Science University Not yet recruiting No outcome recorded
Phase 4 NCT07644923 Aug 2026 → Aug 2028 expected — NYU Langone Health Not yet recruiting No outcome recorded
Phase 4 NCT07696806 Jul 2026 → Jun 2027 expected hyperpigmentation of the skin Sameh Sarsik Enrolling by invitation No outcome recorded
Phase 4 NCT06832878 Jun 2026 overdue — Mayo Clinic Not yet recruiting No outcome recorded
Phase 4 NCT07614087 May → Jun 2026 overdue osteoarthritis Hua Luo Not yet recruiting No outcome recorded
Phase 4 NCT07501884 May → Dec 2026 expected urethral stricture Amjad Alwaal, MD, MSc, FRCSC, FACS Not yet recruiting No outcome recorded
Phase 4 NCT07115056 Apr 2026 → Dec 2028 — Campbell Clinic Withdrawn No outcome recorded
Show all 139 trials opens the full record — a long page
Phase not applicable114 trials · 6 met primary · 3 missed
— NCT07845370 Sep → Dec 2026 expected abdominal wall malformation Dr Mudassar Saeed Pansota Not yet recruiting No outcome recorded
— NCT07530016 Aug 2026 → Dec 2027 expected hyperpigmentation of the skin The First Affiliated Hospital of Xinxiang Medical College Not yet recruiting No outcome recorded
— NCT07714473 Aug → Nov 2026 expected rotator cuff syndrome Hua Luo Not yet recruiting No outcome recorded
— NCT07679139 Jul 2026 → Dec 2027 expected — National Cheng-Kung University Hospital Not yet recruiting No outcome recorded
— NCT07581457 Jun 2026 → May 2027 expected adolescent idiopathic scoliosis Poznan University of Medical Sciences Recruiting No outcome recorded
— NCT07494032 May 2026 → May 2029 expected arthropathy NYU Langone Health Not yet recruiting No outcome recorded
— NCT07540026 May 2026 → Dec 2027 expected upper digestive tract disorder National Cheng-Kung University Hospital Recruiting No outcome recorded
— NCT07432737 Feb 2026 → May 2027 expected bone disorder University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje Recruiting No outcome recorded
— NCT07390799 Feb → Aug 2026 overdue — Ege University Not yet recruiting No outcome recorded
— NCT07318467 Jan → Jun 2026 overdue — Cairo University Not yet recruiting No outcome recorded
Show all 114 trials opens the full record — a long page
Comparator or background therapy250 trials
Phase 0 NCT07817537 Comparator Jan 2026 → Jan 2027 expected — Alexandria University Recruiting No outcome recorded
Phase 0 NCT07280234 Comparator Nov 2024 → May 2025 hyperpigmentation of the skin Hayat Abad Medical Complex, Peshawar Completed No outcome recorded
Phase 0 NCT06509256 Comparator Jul 2024 overdue urticaria Assiut University Not yet recruiting No outcome recorded
Phase 0 NCT06149091 Comparator Dec 2023 → Dec 2024 bronchial disorder China-Japan Friendship Hospital Unknown No outcome recorded
Phase 0 NCT06457360 Comparator Nov 2023 → Jan 2024 cirrhosis of liver British University In Egypt Completed No outcome recorded
Show all 250 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 16

DateIssuerRelease
2025-06-03 Hyloris Developments Regulatory Hyloris Announces U.S. FDA Approval for Tranexamic Acid Ready-to-Use (RTU) hyloris.com ↗
2023-08-09 Palisade Bio Results Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions palisadebio.com ↗
2022-11-22 Palisade Bio Regulatory Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery palisadebio.com ↗
2022-09-29 Palisade Bio Results Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022 palisadebio.com ↗
The oral presentation will include new GI functional data sub-cuts from the highly statistically significant Phase 2 clinical study (NCT05056935) demonstrating LB1148 significantly accelerated the return of post-operative GI function in patients undergoing elective bowel resection.
2022-07-20 Hyloris Developments Results Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures hyloris.com ↗
2022-05-05 Palisade Bio Regulatory Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery palisadebio.com ↗
2022-03-22 Palisade Bio Regulatory Palisade Bio (Nasdaq: PALI) Receives FDA “Study May Proceed” Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery palisadebio.com ↗
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, announced that the Company received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) for a Phase 3 clinical trial to evaluate LB1148 to accelerate the return of bowel function in adult patients undergoing bowel/abdominal surgery.
2022-03-16 Palisade Bio Results Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93% palisadebio.com ↗
2021-07-29 Palisade Bio Results Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery palisadebio.com ↗
Palisade Bio, Inc. (Nasdaq: PALI) and co-development partner Newsoara today announced positive topline Phase 2 clinical trial data that LB1148 had a statistically significant (p=0.0008) effect in accelerating the return of bowel function in patients undergoing elective bowel resection surgery.
2021-05-13 Palisade Bio Regulatory Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery palisadebio.com ↗
2021-04-20 Palisade Bio Results Leading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label Study palisadebio.com ↗
No abdominal adhesions were observed at the time of a follow-up surgery in two patients treated with LB1148.
2021-01-13 Palisade Bio Regulatory Leading BioSciences Announces FDA Fast Track Designation Granted to LB1148 for the Treatment of Postoperative Gastrointestinal Dysfunction Associated with Pediatric Cardiovascular Surgery palisadebio.com ↗

All press releases naming this drug 37 releases

DateIssuerRelease

Evidence & citations 36 cited values

Every value below carries the sentence it was read from. 775 sources stand behind the page.

FieldValueCited text
Known as Tranexamic Acid “Effects of Co-administered Sublingual Misoprostol and Intravenous Tranexamic Acid on Prevention of Postpartum Hemorrhage in Pregnant Women With Twin Pregnancy Undergoing...” NCT03774524 ↗
693

“Whole Blood Clot Stability and Thrombin Generating Capacity Following Treatment With Bypassing Agents (BPA) With and Without and Tranexamic Acid (TXA) in Haemophilia A Patients...” NCT01800435 ↗

“The aim of this study is to compare the effectiveness of combined tranexamic acid (TA) and oxytocin infusion with intravenous carbetocin for prevention of PPH in patients with...” NCT03777878 ↗

“OBJECTIVE: To estimate the effects of adding intravenous tranexamic acid (TA) to the standard active management of third-stage labor to reduce vaginal blood loss during the...” PMID 23023559 ↗ Sep 2012

“Tranexamic acid (TXA) has been routinely delivered in multisegmental spinal decompression and bone graft fusion surgeries with satisfactory outcomes in minimizing gross blood...” PMID 30755256 ↗ Feb 2019

“Patients in the experimental group will receive a loading dose of tranexamic acid (TXA) at a concentration of 1g/10ml over a period of 10 minutes, administered immediately...” NCT05794321 ↗

“Group (II): patients received 1 gm tranexamic acid (TA), (2 ampoules of Capron® 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus Intrauterine Inflated...” NCT03741114 ↗

“10 mg/kg tranexamic acid (Transamine 10% IV/IM Injectable Solution) will be placed into 100 cc physiological saline through the appropriate vascular access and injected within...” NCT06434636 ↗

“Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)” NCT02288923 ↗

“To determine whether intraoperative tranexamic acid (TXA) administration reduced intraoperative blood loss in patients undergoing large meningioma resection.” PMID 42115323 ↗ May 2026

“Patient will receive an intravenous perfusion of 300 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.” NCT03822793 ↗

Show 683 more sources
Known as 1,4-amino-carboxylic acid “1,4-amino-carboxylic acid (tranexamic acid)” PMID 23917458 ↗ Sep 2014
Known as Acide Tranexamique ClinicalTrials.gov intervention name — accepted as the source's own label NCT04085575 ↗
Known as AMCA “Tranexamic acid (AMCA) is a potent antifibrinolytic drug” PMID 3321402 ↗ 1987
Known as Amchafibrin “Tranexamic acid (Amchafibrin) exerts an antihemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.” NCT03386656 ↗
Known as AXA “Tranexamic acid (AXA) and aminocaproic acid (EACA) are synthetic drugs derived from Lysine that competitively inhibit the lysine receptors in the plasminogen and plasmin...” NCT03365999 ↗
Known as Capron “Group (II): patients received 1 gm tranexamic acid (TA), (2 ampoules of Capron® 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision plus Intrauterine Inflated...” NCT03741114 ↗
3

“1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision” NCT03706339 ↗

“1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision” NCT03710330 ↗

“1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Amoun, Cairo, Egypt)” NCT03570710 ↗
Known as Cyclokapron ClinicalTrials.gov intervention name — accepted as the source's own label NCT00697385 ↗
Known as Cyklo-f “Tranexamic acid (Transamin), Cyklokapron, Exacyl, Cyklo-f) is a synthetic lysine derivative” PMID 12825966 ↗ 2003
Known as Cyklokapron “Patients in the TXA group will be given 15 mg/kg of tranexamic acid (Cyklokapron@; Amoun Pharmaceutical Co., SAE) slowly intravenously 30 min before surgery followed by 10 mg/...” NCT03892668 ↗
9

“Subjects will be randomized in a 1:1:1:1 ratio to receive either DepoTXA 400 mg, DepoTXA 800 mg, DepoTXA 1200 mg, or IV TXA (Cyklokapron® 1 gram).” NCT02922582 ↗

“Standard surgery using burr-hole procedure, irrigation and drainage combined withTranexamic acid (Cyklokapron) administration.” NCT03353259 ↗

“Tranexamic acid (Cyklokapron) is utilized extensively for menorrhagia in Australia and the United Kingdom.” NCT00111215 ↗

“1 gm of Tranexamic Acid (Cyklokapron) that will be dissolved in 50 ml of injectable 0.9% saline” NCT05913466 ↗

“Tranexamic acid (Transamin), Cyklokapron, Exacyl, Cyklo-f) is a synthetic lysine derivative” PMID 12825966 ↗ 2003

“topical tranexamic acid (TXA - Cyklokapron; Pfizer, New York, NY)” NCT05357079 ↗

“Tranexamic Acid Injection [Cyklokapron]” NCT05464394 ↗

“Tranexamic Acid (Cyklokapron)” NCT02053363 ↗

“Tranexamic Acid (Cyklokapron)” NCT07245264 ↗
Known as Cyklokapron (tranexamic acid) “Cyklokapron (tranexamic acid)” NCT01535781 ↗
Known as Exacyl “Patient will receive an intravenous perfusion of 300 mg Exacyl (tranexamic acid) intravenous (IV) over 9 minutes, starting at the time of surgical incision.” NCT03822793 ↗
5

“IV Tranexamic acid (Exacyl®): 1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later.” NCT02428868 ↗

“Tranexamic acid (TA) (Exacyl® Sanofi France), an antifibrinolytic drug, reduces bleeding and transfusion need in major surgery and trauma (1).” NCT02797119 ↗

“intravenous administration of 10-mL of tranexamic acid (EXACYL® 1 g/10 ml I.V., solution injectable)” NCT03431805 ↗

“Tranexamic acid (Transamin), Cyklokapron, Exacyl, Cyklo-f) is a synthetic lysine derivative” PMID 12825966 ↗ 2003

“Active comparator : Tranexamic Acid (Exacyl)” NCT02252497 ↗
Known as Kapron “In Tranexamic group (n=111), patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes,...” NCT06060327 ↗
7

“One side of the affected area (the intervention side) will receive topical tranexamic acid at a concentration of 100 mg/mL (Kapron® ampoules, 500 mg/5 mL; Amoun Pharmaceutical...” NCT07795515 ↗

“Women assigned to the study group will receive 1 gr of TXA injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.” NCT02350179 ↗

“Tranexamic acid (Kapron ampoules, 100 mg/mL) is diluted under aseptic conditions to a final concentration of 10 mg/mL” NCT07540702 ↗

“soaked in Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)” NCT05439694 ↗

“will receive 1 g tranexamic acid (2 ampoules of kapron 500 mg, kapron®, Amoun, Egypt)” NCT05806307 ↗

“using a sterile towel soaked with 2g tranexamic acid (Kapron, Amoun, Cairo, Egypt)” NCT06515535 ↗

“Tranexamic acid (Kapron, Amoun Pharmaceuticals SAE, Egypt. 5ml Amp, 100mg /1ml)” NCT05434533 ↗
Known as Kepron “Tranexamic acid (Kepron, Amoun, Egypt) was given slowly intravenously over 10 minutes just before the skin incision of elective cesarean section to group A.” NCT03351686 ↗
Known as LB1148 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05470387 ↗
3

NCT05056935 ↗

NCT02836470 ↗

NCT04390217 ↗
Known as Lysteda “Medications: tranexamic acid (Lysteda, Pierre Fabre Mexico) or aminocaproic acid (Amikar, Wyeth), as appropriate, will be administered orally three times (administering 2...” NCT03365999 ↗
Known as Marcan-Tranexamic Acid “Marcan-Tranexamic Acid 500 mg oral tablet over-encapsulated to match the placebo.” NCT05713630 ↗
Known as Sandoz-Tranexamic Acid “Sandoz-Tranexamic Acid 100 mg/mL solution for injection via intravenous (IV) added to a 100mL infusion bag of NaCl 0.9% and infused by slow intravenous injection over 20 minutes.” NCT05713630 ↗
Known as TNA “Tranexamic acid (TNA) is an antifibrinolytic agent that inhibits fibrinolysis by blocking the activation of plasminogen.” NCT07174895 ↗
1

“Despite the documented blood-saving effects of tranexamic acid (TNA) in total knee arthroplasty (TKA)” PMID 23592025 ↗ Apr 2013
Known as tnx acid “group 1 (TRANEXEL 250 mg/5 mL) patients administered 250 mg tnx acid during the whole bimaxillary orthognathic surgery” NCT06301204 ↗
Known as TRAN “BACKGROUND: To assess the equivalence of tranexamic acid (TRAN) versus synthetic oxytocin (OXY) in reducing post-partum blood loss, in full-term patients (37-42 weeks), at low...” PMID 38873634 ↗ May 2024
Known as Tranexam OrPha “Tranexamic acid 10mg/kg (Tranexam OrPha 1000 mg/10 ml, OrPha Swiss GmbH, Küsnacht, Switzerland) will be administered 15 -30 minutes prior to surgery followed by infusion of...” NCT04625530 ↗
Known as Tranexamic acid (CYKLOKAPRON) (Pfizer, New York, NY). “Tranexamic acid (CYKLOKAPRON) (Pfizer, New York, NY).” NCT06419075 ↗
Known as tranexamic acid (TXA) “tranexamic acid (TXA)” NCT05639686 ↗
Known as Tranexamic acid injection “Drug: Tranexamic acid injection” NCT05236569 ↗
1

“Drug: Tranexamic acid injection” NCT04622397 ↗